Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation (Journal of Experimental and Clinical Cancer Research (2019) 38 (474) DOI: 10.1186/s13046-019-1442-2)

Ssu Chuan Lai, Yu Ting Su, Ching Chi Chi, Yung Che Kuo, Kam Fai Lee, Yu Chih Wu, Pei Chi Lan, Muh Hwa Yang, Te Sheng Chang*, Yen Hua Huang

*Corresponding author for this work

Research output: Contribution to journalComment/debate

3 Scopus citations

Abstract

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with 'DMT1' now corrected to read 'DNMT1'(Figure Presented). The authors sincerely apologize for the inconvenience caused to the readers.

Original languageEnglish
Article number10
JournalJournal of Experimental and Clinical Cancer Research
Volume39
Issue number1
DOIs
StatePublished - 13 Jan 2020

Fingerprint

Dive into the research topics of 'Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation (Journal of Experimental and Clinical Cancer Research (2019) 38 (474) DOI: 10.1186/s13046-019-1442-2)'. Together they form a unique fingerprint.

Cite this